Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253240 | 0.85 | ALDH1A1 (0.59) | HRH3TRPV1GAARBP4HSD11B1 | |
| SCHEMBL27761289 | 0.84 | HSD11B1 (0.55) | HRH3TRPV1GAARBP4HSD11B1 | |
| SCHEMBL14338319 | 0.75 | CYP2C19 (0.48) | TRPV1ALDH1A1MALT1 | |
| SCHEMBL1369593 | 0.72 | EPHX2 (0.66) | GAARBP4HSD11B1EPHX2 | |
| SCHEMBL1367550 | 0.72 | EPHX2 (0.52) | TRPV1GAAHSD11B1EPHX2 | |
| SCHEMBL4913516 | 0.72 | DGAT1 (0.49) | TRPV1RBP4ALDH1A1MALT1EPHX2 | |
| SCHEMBL1252470 | 0.72 | TRPV1 (0.66) | HRH3TRPV1GAARBP4HSD11B1 | |
| SCHEMBL3216080 | 0.72 | TRPV1 (0.69) | HRH3TRPV1GAARBP4HSD11B1 | |
| SCHEMBL15962957 | 0.71 | OPRM1 (0.58) | HRH3TRPV1GAARBP4HSD11B1 | |
| SCHEMBL30582915 | 0.71 | EPHX2 (0.68) | HRH3TRPV1GAARBP4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-15 | — | — | US | disclosed |
| EP-2024368-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| EP-2024368-A2 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | HRH3 32/4885TRPV1 1/4885GAA 3383/4885 |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | HRH3 32/4885TRPV1 1/4885GAA 3383/4885 |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | HRH3 35/4885TRPV1 1/4885GAA 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.